Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smith & Nephew H1 profits come in ahead of expectations

(Sharecast News) - Medical equipment manufacturer Smith & Nephew said on Thursday that interim profits had come in ahead of market expectations, thanks in no small part to the company's 12-point turnaround plan.

Smith & Nephew said first-half revenues were up 4.3% at $2.8m, while operating profits rallied 19.5% to $328.0m and trading profits were almost 13% higher at $471.0m.

Cash generated from operations rose from $215.0m in H123 to $368.0m in H124 as S&N made marked improvements in trading cash flow conversion, rising to 60% from 26% at the same time a year earlier.

The FTSE 100-listed group credited much of its improved performance to its 12-point plan, which includes winning market share and fixing its orthopaedics division, as well as regaining momentum across its robotics, trauma, and knee and hip implant units.

Chief executive Deepak Nath said: "Today's results are further evidence of the good progress we are making transforming Smith & Nephew into a higher growth and more profitable business.

"The methods we employed in achieving these successes give me confidence that we will also turn around US hip and knee Implants and we expect to see a step up through the second half of the year."

As of 0900 BST, S&N shares were up 7.48% at 1,207.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.